

DESCRIPTION

Title of the Invention

ANTIBODIES FOR DETECTING MICROORGANISMS

5

DESCRIPTION OF BACKGROUND ART

Field of the Invention

The present invention pertains to antibodies useful in the detection of various microorganisms, particularly bacteria, and a method of detecting microorganisms, reagent kits for detection of microorganisms that use said antibodies, and a method for preparing specific antibodies for detecting microorganisms.

Moreover, the present invention is valuable to the drug industry, particularly for diagnostic medicine of microbial infections with an emphasis on bacteria.

Prior Art

Diagnosis of microbial infection is confirmed by detection of the causative pathogen from the infected area or by detection of antibodies to the causative pathogen in serum and body fluids. Detection of the causative pathogen is particularly important in the sense that it makes quick treatment to the patient possible.

Detection of the causative pathogen of infections

can be generally classified as cultivation and identification methods, whereby the causative pathogen is separated and cultivated and then identified based on its biochemical properties;

5 genetic diagnosis, whereby amplification by PCR, etc., is performed based on specific genes of the causative pathogen and thus the causative pathogen is detected; or immunological methods, whereby the causative pathogen is detected using a specific  
10 reaction of antibody with surface antigen marker of the causative pathogen. However, it takes time to obtain results by cultivation and identification methods or genetic diagnosis methods. Therefore, diagnosis by immunological methods is commonly used  
15 because the causative pathogen can be detected within a short time with high sensitivity and the patient can be quickly and appropriately treated.

Depending on the bacterial species, a variety of marker antigens and antibodies can be used alone or,  
20 in combination to detect the causative pathogen of infections by conventional immunological methods.

For instance, it is known that lipopolysaccharide (LPS), which is a genus-specific antigen of *Chlamydia*, is present as an antigen determinant  
25 (Stephens, R., et al.: *J. Immunol.*, 128:1083-89, 1982, Caldwell, M.D.: *Inf. Immun.*, 44:306-14, 1984), and antibodies to LPS are used as the reagent

antibody in a variety of diagnostic kits,  
particularly for the detection of *Chlamydia*  
*trachomatis*.

Moreover, Ellena M. Peterson et al., (Infection  
5 and Immunity, 59(11), 4147-4153, 1991) and Byron E.  
Batteiger et al., (Infection and Immunity, 53(3),  
530-533, 1986) have reported monoclonal antibodies to  
major outer membrane protein (MOMP) of the genus  
*Chlamydia* respectively.

10 Publication of unexamined Japanese patent  
application No. 298/1988 discusses an immunodetection  
method based on ~~the~~ western blot method that uses a  
monoclonal antibody to an approximately 43 kilo  
Dalton membrane protein antigen of *Mycoplasma*  
15 *pneumoniae*.

Moreover, a method of preparing monoclonal  
antibody to *Haemophilus influenzae* and a diagnostic  
method that uses said antibody are presented in  
Publication of unexamined Japanese patent application  
20 No. 148859/1987 (Japanese Patent No. 64065/1994).

Proteins of approximately 20 kilo Dalton isolated  
from the sodium cholate extract of the outer membrane  
vesicle of *Neisseria gonorrhoeae* strain BS4 (NCTC  
11922) are documented and preparation of hybridomas  
25 using said substance is disclosed in British Patent  
Application No. 2,172,704. Moreover, European Patent  
Document no., EP 419238 A1 describes preparation of a

monoclonal antibody, which can bind to a protein of approximately 14 kilo Dalton prepared by using *Neisseria gonorrhoeae* as an immunogen and a method for the preparation of such a monoclonal antibody.

5 Additionally, a method of detecting the same *Neisseria gonorrhoeae* using monoclonal antibody to lipopolysaccharide (LPS) is mentioned in Canadian Patent Application No. 1,220,147.

10 However, there are problems with said antibodies and detection methods based on those antibodies in that species specificity to microorganisms is insufficient for proper diagnosis. The antibodies do not detect all serum types as plural surface antigens present within one species.

15 Marker antigens used in these prior arts are not standardized so that microorganisms can be detected using a same functional molecule (for instance, protein, LPS or surface polysaccharide component with the same function) which is generally present in  
20 cells of various microorganisms and which changes during the course of evolution of the microorganisms as a marker, and an immunodiagnostic method based on the concept of detecting the difference in antigenicity between bacterial species using one  
25 molecule as a standard is not known.

#### DISCLOSURE OF THE INVENTION

The present invention strives to present

antibodies to the same molecule for different  
microorganisms as a standard marker antigen to make  
ideal microorganism detection and immunodiagnosis  
possible, particularly antibodies to the molecular  
5 segment in the same intracellular functional  
component molecule for all microorganisms to be  
detected that changes during the course of evolution  
of microorganisms, a method of detecting  
microorganisms, which is species specific and can  
10 cover almost all serum types, a reagent kit for  
detection of microorganisms that use said antibody,  
and a method for preparing a specific antibody used  
for detection of microorganisms.

The present inventors discovered a protein with  
15 the same function, preserved in all microorganisms as  
a useful antigen protein. Usually, it is expected  
that a structural change of such a protein is  
extremely small. However, surprisingly it was found  
that the antigen epitope(s) of this protein has  
20 specificity to certain species or genus of  
microorganisms, and that the antibody for this  
protein not only has potentialities of being used for  
specifically identifying species or genus of  
microorganisms, but also is capable of detecting all  
25 serotypes of the target microorganisms.

The inventors focused on intracellular molecule  
that are present in all microbial cells and differ

between microorganisms in terms of its amino acid sequence, particularly ribosomal protein L7/L12, which is a member of ribosomal proteins. Ribosomal protein L7/L12 is a protein with a molecular weight of approximately 13 kilo Daltons and is known to exist as a ribosomal protein essential in protein synthesis. Progress has been made in understanding the complete amino acid sequence of the protein from several microorganisms including particularly *Escherichia coli* and *Baccillus subtilis*, etc., and 50 % to 65 % homology of the amino acid sequence between the microorganisms has been confirmed.

The inventors focused on the fact that even though there are similarities in said molecule between different microorganisms, this molecule also has a structural segment that is unique to each microorganism and discovered that it is possible to detect various microorganisms with species specificity and to detect all serotypes within the same species by using antibody to the protein. As a result of attempting to develop a technology for immuno-diagnosis of microorganism species using antibody specific to, for instance, *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria gonorrhoeae*, the inventors completed the present invention upon discovering that antibody specific to said protein of each species of microorganisms can be

obtained and species-specific detection of different bacteria is possible using said antibody.

The present invention relates to an antibody used for detecting microorganisms, a method of detecting  
5 microorganisms using the antibody, a reagent kit for detecting microorganisms using the antibody, and a method for preparing specific antibodies for detecting microorganisms.

1) Antibodies which are antibodies to ribosomal  
10 protein of microorganisms and which react specifically with said microorganisms.

2) The antibodies described in 1) above, where the ribosomal protein of the microorganisms is ribosomal protein L7/L12.

15 3) The antibodies described in 1) or 2) above, where said microorganisms are microorganisms, which cause a sexually transmitted disease (STD).

4) The antibodies described in 1) or 2) above, where said microorganisms are microorganisms which  
20 cause respiratory tract infection.

5) The antibody described in 4) above, where the causative microorganisms of respiratory tract infection are microorganisms of *Haemophilus influenzae*.

25 6) The antibody described in 4) above, where the causative microorganisms of respiratory tract infection are microorganisms of *Streptococcus*

*pneumoniae*.

7) The antibody described in 3) above, where the causative microorganisms of sexually transmitted diseases (STD) are microorganisms of *Neisseria gonorrhoeae*.

8) The antibody described in 7) above, which is the antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae* and which recognizes a continuous amino acid sequence moiety from 5 to 30 amino acids including the 115th alanine in the amino acid sequence of Sequence ID No. 22 of the Sequence Table.

9) A method of detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

10) A method of detecting microorganisms, which is characterized by the fact that any antibody described in 1) to 8) above is used.

11) A reagent kit for detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

12) A reagent kit for detecting microorganisms, which is characterized by the fact that any antibody described in 1) to 8) above is used.

13) A method of preparing any antibody described in 1) to 8) above, characterized by the fact that



ribosomal protein L7/L12 of microorganisms obtained by a gene manipulation procedure or by isolation from microorganisms, peptide moiety thereof, or a synthesized peptide corresponding to the peptide moiety is used as an immunogen.

The present invention will now be explained in detail.

Sub B1  
Sequences No. 1 and No. 2 in the Sequence Table are the DNA sequence of the ribosomal protein L7/L12 gene of *Haemophilus influenzae* and corresponding amino acid sequence. Sequences No. 3 and No. 4 are the DNA sequence of the ribosomal protein L7/L12 gene of *Helicobacter pylori* and the corresponding amino acid sequence. Sequences No. 5 and No. 6 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Streptococcus pneumoniae*. Sequences No. 7 and No. 8 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*. Sequences No. 9 and No. 10 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria meningitidis*. Sequence No. 11 and Sequence No. 12 in the Sequence Table are the primers DNA for PCR used to acquire the ribosomal protein L7/L12 gene from *Haemophilus influenzae*. Sequences No. 13 and No. 14 in the Sequence Table are the primer DNA for PCR used

to acquire the ribosomal protein L7/L12 gene from *Streptococcus pneumoniae*. Sequences No. 15 and No. 16 in the Sequence Table are the primer DNA for PCR used to acquire the ribosomal protein L7/L12 gene from *Neisseria gonorrhoeae*. Sequences No. 17 and No. 18 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Haemophilus influenzae*. Sequences No. 19 and No. 20 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Streptococcus pneumoniae*. Sequences No. 21 and No. 22 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*.

Furthermore, the left and right terminals of the amino acid sequences entered in the Sequence Table are amino group (referred to below as the N terminal) and carboxyl group terminals (referred to below as the C terminal), respectively, and the left terminal and right terminal of the base sequence is the 5' terminal and the 3' terminal, respectively.

Moreover, the series of biomolecular experiments of gene preparation mentioned in this text can be performed by methods entered in standard experimental manuals. "Molecular cloning: A laboratory manual," Cold Spring Harbor Laboratory Press, Sambrook, J. et al. (1989), is an example of the aforementioned

standard experimental manual.

The term microorganism in the present invention refers to all species of microorganisms, including bacteria, yeast, mold, *Actinomyces*, *rickettsia*, etc.,  
5 but bacteria in particular, pose a problem in terms of diagnosis of microbial infections.

The term "antibody which reacts specifically with microorganisms" as used in the present invention means an antibody, which reacts specifically with a  
10 species or group of microorganisms. An antibody, which reacts specifically with a species of microorganisms, is particularly useful for the diagnosis of microbial infection diseases.

In the present invention, causative  
15 microorganisms of STD (sexually transmitted disease) include, but are not limited to, *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Candida albicans*, *Treponema pallidum*, and *Ureaplasma urealyticum*.

In the present invention, causative  
20 microorganisms of respiratory tract infection include, but are not limited to, *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Pseudomonas*  
25 *aeruginosa*, *Streptococcus sp. Group-A*, *Mycobacterium tuberculosis*, *Legionella pneumophila*, and *Aspergillus spp.*

The term antibody in the present invention means a polyclonal antibody or monoclonal antibody that can be made using the entire length or only a partial peptide of said ribosomal protein. Although there are  
5 no special restrictions to the peptide length for making the antibody, the segment should be of the length characterizing the ribosomal protein L7/L12, and a peptide of 5 amino acids or longer, particularly 8 amino acids or longer, is preferred.

10 Antiserum containing antibody (polyclonal antibody) that identifies ribosomal protein L7/L12 can be obtained by inoculating laboratory animals with adjuvant and a peptide or the full length protein as it is or when necessary, after being cross linked  
15 with a carrier protein such as KLH (keyhole-limpet hemocyanin) and BSA (bovine serum albumin) and recovering the serum. Moreover, the antibody can be used after it has been purified from the antiserum. The laboratory animals that are inoculated include  
20 sheep, horses, goats, rabbits, mice, rats, etc., and sheep, rabbits, etc., are particularly preferred for preparation of polyclonal antibody. Moreover, monoclonal antibody can also be obtained by  
25 mice are preferred in this case. The entire length of the said protein, or its partial peptide consisting amino acid residues of 5 or more,

preferably 8 or more, residues that has been fused with GST (glutathione S-transferase), etc., can be purified and used as antigen, or it can be used as antigen without being purified. The antibody can also be the genetic recombination antibody expressed cellularly using immunoglobulin genes that have been separated by a variety of methods in manuals ("Antibodies: A Laboratory manual," E. Harlow et al., Cold Spring Harbor Laboratory), cloning methods, etc.

Antibody to ribosomal protein L7/L12 that can be employed as the marker antigen of the present invention can be obtained by the following 3 methods, and other similar methods as well. The methods, however, are not limited to these.

a) The desired antibody can be acquired by synthesizing a peptide fragment consisting of 5-30 amino acids for microorganisms with a known ribosomal protein L7/L12 genetic sequence and amino acid sequence using the region least similar to the amino acid sequence of said protein of another microorganisms and making polyclonal antibody, or monoclonal antibody, using this peptide fragment as the immunogen.

Moreover, it is possible to acquire the entire sequence of said gene by using a conventional genetic procedure, such as gene amplification by PCR with the

DNA sequence at both terminals of said known genetic sequence as the probe, or hybridization using the sequence of a homologous segment as the template probe.

5        Then, a fused gene with another protein gene is constructed and said fused gene is inserted into the host by conventional gene insertion methods using *Escherichia coli*, etc., as the host and expressed in large quantities. The desired protein antigen can  
10 then be acquired by purifying the expressed protein by affinity column methods with antibody to the protein that was used as the fusion protein. In such a case, even if antibody to the amino acid segment conserved within microorganisms is acquired, it does  
15 not coincide with the purpose of the present invention because the full length of ribosomal protein L7/L12 becomes the antigen. Consequently, hybridoma that produces monoclonal antibody to the antigen that has been obtained by this method is  
20 acquired by conventional methods and the desired antibody can be obtained by selecting a clone that produces antibody that will react only with the desired microorganisms.

b) First, since there is 50 to 60% homology  
25 between bacterial species in terms of their ribosomal protein L7/L12 amino acid sequence, it is possible to easily acquire said protein genes for microorganisms

with unknown L7/L12 amino acid sequence by  
conventional genetic procedures, such as gene  
amplification of a specific sequence segment by PCR  
methods based on the sequence of the homologous  
5 segments of the amino acid sequence, or hybridization  
with the homologous segments as the template probe,  
using bacteria having a known ribosomal protein  
L7/L12 amino acid sequence.

Then, a fused gene with another protein gene is  
10 constructed and said fused gene is inserted into the  
host by conventional gene insertion methods using  
*Escherichia coli*, etc., as the host and expressed in  
large quantities. The desired protein antigen can  
then be acquired by purifying the expressed protein  
15 by affinity column methods with antibody to the  
protein that was used as the fusion protein. In such  
a case, even if antibody to the amino acid segment  
conserved within microorganisms is acquired, it does  
not coincide with the purpose of the present  
20 invention because the full length of ribosomal  
protein L7/L12 becomes the antigen. Consequently,  
hybridoma that produces monoclonal antibody to the  
antigen that has been obtained by this method is  
acquired by conventional methods and the desired  
25 antibody can be obtained by selecting a clone that  
produces antibody that will react only with the  
desired microorganisms.

c) Ribosomal protein L7/L12 that has been purified to a high purity can also be obtained by another method, in the case where the amino acid sequence of the ribosomal protein L7/L12 is unknown  
5 whereby a peptide of 5 to 30 amino acids corresponding to the common sequence segment retained in the microorganisms is synthesized from the known amino acid sequence of the ribosomal protein L7/L12, and polyclonal antibody or monoclonal antibody to  
10 this peptide sequence is made by conventional methods. Then the highly purified Ribosomal protein L7/L12 from disrupted microorganisms is obtained by affinity column chromatography using said antibody.

If purity of the protein is insufficient, it can  
15 be purified by conventional methods, such as ion exchange chromatography, hydrophobic chromatography, gel filtration, etc., after which the eluted fraction of ribosomal protein L7/L12 is identified by western blotting, etc., using antibody that was made to  
20 obtain the pure fraction. The desired antibody can be obtained by acquiring hybridoma or polyclonal antibody by conventional methods using the pure ribosomal protein L7/L12 antigen that has been obtained and selecting hybridoma or polyclonal  
25 antibody that will react specifically with the desired bacteria, as in b).

The antibody of the present invention specific to



a variety of microorganisms that has been obtained by the methods in a) through c), etc., can be used in a variety of immunoassay methods to obtain diagnostic reagent kits specific to a variety of microorganisms.

5 For example, this antibody can be used in aggregation reactions where antibody is adsorbed on polystyrene latex particles, ELISA, which is a conventional technology performed in a microtiter plate, conventional immunochromatography methods, sandwich  
10 assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or with enzyme or phosphor, and magnetic microparticles coated with capture antibody, etc., are used, etc.

15 The term detection methods for microorganism using antibody means detection methods that use conventional immunoassay such as aggregation reactions where antibody is adsorbed on polystyrene latex particles, ELISA, which is a conventional  
20 technology performed in a microtiter plate, conventional immunochromatography methods, sandwich assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or with enzyme or phosphor, and magnetic  
25 microparticles coated with capture antibody, etc., are used, etc.

Moreover, the optical immunoassay (OIA)

technology described in International Patent  
Application Japanese Laid-open (Toku-Hyou) No.  
509565/1995, in which microorganisms are detected by  
an optical interference induced by an antibody  
5 reaction on the optical thin film which is formed by  
silicone or silicon nitride, is a useful detection  
method using an antibody.

Moreover, treatment with an extraction reagent  
that uses a variety of surfactants, beginning with  
10 Triton X-100 and Tween-20, enzyme treatment with an  
appropriate enzyme, such as protease, etc., known  
methods whereby the cell structure is disrupted,  
beginning with disruption of the microorganism by  
physical methods, can be used to extract the  
15 intracellular marker antigen from the necessary  
microorganism in said detection method. However, it  
is preferred that the extraction conditions be  
designed using a combination of surfactants, etc., so  
that the conditions are optimized for extraction of  
20 each microorganism with reagents.

Moreover, the term a reagent kit for detection of  
microorganisms using antibody means a reagent kit  
that uses said detection method.

For instance, in the case of obtaining the  
25 specific antibody to *Haemophilus influenzae*, which is  
of extreme diagnostic significance as a causative  
pathogen of pneumonia, bronchitis, meningitis, etc.,

the amino acid sequence and DNA sequence of ribosomal protein L7/L12 is entered in data bases, etc.

1 The amino acid and DNA sequence of ribosomal protein L7/L12 of *Haemophilus influenzae* are shown in  
5 "Sequences No. 1 and No. 2."

1 Consequently, in the case of this bacteria, it is possible to similarly compare the amino acid sequence of ribosomal protein L7/L12 with the same protein of, for instance, *Helicobacter pylori*, which is shown in  
10 "Sequence No. 3 and No. 4," and synthesize a peptide of 5 to 30 amino acids for the segment of low homology and make polyclonal antibody or monoclonal antibody specific to *Haemophilus influenzae* using this peptide.

15 In the case of a specific polyclonal antibody, it is preferred that IgG fraction be obtained by purification of the antiserum of immunized laboratory animals with a protein A column, etc., and affinity purification be performed with the synthetic peptide used in immunization of the laboratory animals.

20 Moreover, PCR primers based on the sequences of N-terminal and C-terminal, for example, the PCR primers shown in Sequences No. 11 and No. 12 in the Sequence Table, were designed from the DNA sequence  
25 of ribosomal protein L7/L12 of *Haemophilus influenzae*. Utilizing homology of the PCR primers, DNA fragments amplified by the PCR method or the like

using genomic DNA which is extracted from cultivated *Haemophilus influenzae* can be acquired by a conventional method. The entire length of the gene for ribosomal protein L7/L12 of *Haemophilus influenzae* can be acquired by the analysis of the DNA sequence information of these fragments.

The ribosomal protein L7/L12 gene of *Haemophilus influenzae* thus acquired forms a fusion protein gene with, for instance, GST etc., and expression vector is constructed using the appropriate expression plasmid, *Escherichia coli* is transformed and large quantities of said protein can be expressed. A suitable amount of the transformed *Escherichia coli* is cultivated and the crushed bacterial fluid that is recovered is purified by an affinity column using GST to obtain the ribosomal protein L7/L12 and GST fusion protein of *Haemophilus influenzae*. It is also possible to acquire the target specific monoclonal antibody by establishing plural hybridomas using said protein as it is or GST moiety fragments cut from the protein by protease or the like, as an antigen protein and selecting the antibody which exhibits a specific response to *Haemophilus influenzae* bacteria, or a disrupt fluid of the bacteria, or ribosomal protein L7/L12 of *Haemophilus influenzae*.

Moreover, the amino acid sequence and the DNA sequence of ribosomal protein L7/L12 of *Streptococcus*

pneumoniae which is also highly significant as a diagnostic agent for respiratory infection diseases as well as *Haemophilus influenzae*, are known from descriptions in data bases and the like. The amino acid and DNA sequences of ribosomal protein L7/L12 of *Streptococcus pneumoniae* are shown in Sequences No. 5 and No. 6 of sequence table.

1WS  
B6  
It is therefore possible to acquire a polyclonal antibody or monoclonal antibody which is specific to *Streptococcus pneumoniae* by designing a PCR primer, the PCR primer shown by Sequence ID No. 13 or 14 in the Sequence Table, for example, based on the sequences of N-terminal and C-terminal of DNA sequence of Ribosomal Proteins L7/L12 of *Streptococcus pneumoniae* in the same manner as in the case of *Haemophilus influenzae*, and processing thereafter in the same manner as in the case of *Haemophilus influenzae*.

The hybridoma AMSP-2 which produces the monoclonal antibody specific to *Streptococcus pneumoniae* has been deposited with the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan, on July 28, 1999, with the deposition number FERM BP-6807.

Moreover, although the DNA and amino acid

sequences of the ribosomal protein L7/L12 of, for instance, *Neisseria gonorrhoeae*, which is the causative pathogen of gonorrhea and has been shown to have diagnostic significance as a typical causative pathogen of STD, were unknown, a major part of the DNA sequence and amino acid sequence, which was determined by the *Neisseria Gonorrhea Genome Project* at Oklahoma University, USA, is disclosed on the Internet.

When part of the known DNA sequence of ribosomal protein L7/L12 was used to probe the existence of DNA fragments with a similar sequence, it was found that DNA sequence corresponding to the ribosomal protein L7/L12 gene is present and it was possible to obtain data on its entire DNA sequence. The entire base sequence and corresponding amino acid sequence of the ribosomal protein L7/L12 gene of this *Neisseria gonorrhoeae* are shown in Sequences No. 7 and No. 8 of the sequence table.

It is therefore possible to acquire the target antibody which is specific to *Neisseria gonorrhoeae* having the entire or partial Ribosomal Protein L7/L12 of *Neisseria gonorrhoeae* as an antigen by designing a PCR primer, the PCR primer shown by Sequence ID No. 15 or 16 in the Sequence Table, for example, based on the sequences of N-terminal and C-terminal of DNA sequence of Ribosomal Protein L7/L12 of *Neisseria*

gonorrhoeae in the same manner as in the case of  
*Haemophilus influenzae*, and *Streptococcus pneumoniae*,  
and processing thereafter in exactly the same manner  
as in the case of *Haemophilus influenzae* or  
5 *Streptococcus pneumoniae*.

LWS  
BG  
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
22

be used in all known types of immunoassay, such as aggregation whereby said antibody is adsorbed on polystyrene latex, ELISA, which is a conventional technology performed in a microtiter plate, conventional immunochromatography, sandwich assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or enzymes or phosphor, and magnetic particles coated with capture antibody are used, etc.

10 Moreover, antibody that is made based on the present invention can simultaneously function in any of these immunoassay methods as a so-called capture antibody that captures said antigen protein in solid or liquid phase and a so-called enzyme-labeled antibody by modification using an enzyme, such as 15 peroxidase and alkali phosphatase, etc., by conventional methods.

#### BEST MODE FOR CARRYING OUT THE INVENTION

20 The following examples are given to explain the present invention in actual terms, the present invention not being restricted to these examples.

##### Example 1

Cloning of ribosomal protein L7/L12 genes from  
*Haemophilus influenzae*

1 After inoculating an appropriate amount of *Haemophilus influenzae* strain ATCC9334 (IID984) (obtained from Tokyo University School of Medicine



Laboratories) in a chocolate agar culture medium, the strain was cultivated for 24 hours in a CO<sub>2</sub> incubator under conditions of 37 °C and 0.5 <5.0> % CO<sub>2</sub>. The colonies that grew were suspended in a TE buffer (manufactured by Wako Pure Chemical Co., Ltd.) to a final concentration of approximately 5 x 10<sup>9</sup> CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifuge tube and centrifuged for 2 minutes at 10,000 rpm. The supernatant was discarded. The sediment was resuspended in 567 µl TE buffer. Then 30 µl 10 % sodium dodecylsulfate (SDS) and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated for another hour at 37 °C. Next, after adding 80 µl 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and thoroughly mixing the product, it was incubated for 10 minutes at 65 °C. Next, 700 µl chloroform-isoamyl alcohol solution at a volume ratio of 24:1 was added and stirred well. The solution was centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm using a microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifuge tube containing 1 ml

70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the  
5 product was centrifuged for 5 more minutes.

Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively according  
10 to E5, Spectrophotometric determination of the amount of DNA or RNA "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

PCR (polymerase chain reaction) was performed  
15 using 10 ng of this genomic DNA. Taq polymerase (Takara Co., ltd., code R001A) was employed for PCR. Then 5 µl of buffer, 4 µl dNTP mixture, and 200 pmol each of synthetic oligonucleotide-A, shown in Sequence No. 11 of the Sequence Table and synthetic  
20 oligonucleotide-B, shown in Sequence No. 12 of the Sequence table were added to the enzyme to bring the final volume to 50 µl.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes  
25 at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed

in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp  
5 cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was  
10 purified with Suprec01 (Takara Co., Ltd.) and then inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. This same vector can function as an expression vector for the desired molecule, which can express fused protein with GST protein, by  
15 insertion of the desired gene fragment into the appropriate restriction endonuclease site.

Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA ligase  
20 (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* one-shot competent cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing  
25 50 µg/ml ampicillin (Sigma). The plate was then set-aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2 ml

L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37 °C for 8 hours and the bacteria were recovered and the plasmid was separated using Wizard  
5 Miniprep (Promega) in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had  
10 been inserted was determined using said clone.

*Handwritten:* 125  
*Handwritten:* 1311

(Determination of the base sequence of the inserted DNA fragment was performed using the Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready  
15 Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5 µl reaction stock solution, 4.0 µl T7 promoter primer at 0.8 pmol/µl (Gibco BRL) and 6.5 µl of template DNA for sequencing at 0.16 µg/µl were added to a microtube with a capacity of  
20 0.5 ml, mixed and superposed with 100 µl mineral oil. PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the  
25 reaction was completed, 80 µl sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with

phenol-chloroform. Ten ml <microliters> 3 M sodium acetate (pH 5.2) and 300 µl ethanol were added to 100 µl aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4 µl 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and applied to sequencing.

One of the 5 clones obtained had homology of the sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Neisseria gonorrhoeae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 17 and No. 18 of the Sequence Table. This gene fragment clearly codes for *Haemophilus influenzae* ribosomal protein L7/L12.

#### Example 2

Mass expression in *Escherichia coli* and purification of ribosomal protein L7/L12 from *Haemophilus influenzae*

Fifty milliliters *Escherichia coli* into which

expression vector had been inserted were cultivated overnight in LB at 37 °C. Then 500 ml YT medium at concentration that was twice that of the  
aforementioned culture was heated at 37 °C for 1  
5 hour. Fifty milliliters of the *Escherichia coli* solution that had been cultivated overnight were introduced to 500 ml of the aforementioned medium. One hour later, 550 µl 100 mM isopropyl β-(D)-thiogalactopyranoside (IPTG) were introduced and  
10 cultivated for 4 hours. The product was then recovered and introduced to centrifugation tube at each 250 ml and centrifuged for 10 minutes at 7,000 rpm.

The supernatant was discarded and dissolved in 25  
15 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

Furthermore, 1.25 ml 10 % Nonidet P-40 (NP-40) and 125 µl 1 M MgCl<sub>2</sub> were added and transferred to a plastic tube. Sonication was performed 1 minute x 5  
20 times while ice cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

Next, the aforementioned supernatant was adsorbed on a glutathione agarose column conditioned with  
25 phosphate-buffered saline (PBS).

Then the column was washed with twice the bed volume using a washing solution containing 20 mM Tris

buffer at a pH of 7.4, 4.2 mM  $\text{MgCl}_2$ , and 1 mM dithiothreitol (DTT). Elution was performed with 50 mM Tris buffer at a pH of 9.6 containing 5 mM glutathione. The protein content in the fraction was determined by the pigment bonding method (Bradford method; BioRad Co.) and the main fraction was acquired.

Purity of the purified ribosomal protein L7/L12/GST fused protein that was obtained was confirmed by electrophoresis to be approximately 75 %, showing that a purity satisfactory for an immunogen could be guaranteed.

### Example 3

#### Preparation of monoclonal antibody to ribosomal protein L7/L12 of *Haemophilus influenzae*

First, 100  $\mu\text{g}$  fused protein antigen of ribosomal protein L7/L12/GST of *Haemophilus influenzae* were dissolved in 200  $\mu\text{l}$  PBS and then 200  $\mu\text{l}$  Freund's complete adjuvant were added and mixed and emulsification was performed. Two-hundred microliters were injected intraperitoneally to immunize mice.

Then the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4 weeks, and after 6 weeks. Two-fold the concentration of antigen emulsion was injected intraperitoneally after 10 weeks and after 14 weeks. The spleen was

excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing  $2 \times 10^7$  myeloma cells per  $10^8$  spleen cells from mice, which had been recovered  
5 aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1,500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were  
10 obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5  $\mu$ g/ml MC-210, and 10 % FCS for 1  
15 weeks, and then further cultivating the cell strain for 1 week with an RPMI 1640 medium containing 10 % FCS.

Thirty milliliters of RPMI 1640 culture medium 50 ml that had been kept at 37 °C were added to the  
20 mixed cell sample and centrifuged at 1,500 rpm. After removal of the supernatant, 1 ml 50 % polyethylene glycol that had been kept at 37 °C was added and stirred for 2 minute. 10 ml RPMI 1640 medium kept at 37 °C were added and the solution was  
25 vigorously mixed for approximately 5 minutes as it was suctioned and evacuated from a sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm



and removal of the supernatant, 30 ml HAT medium were added to bring the cell concentration to  $5 \times 10^6$  cells/ml. This mixture was stirred till uniform and then poured, 0.1 ml at a time, into a 96-well culture plate and cultivated at 37 °C under 7 % CO<sub>2</sub>. HAT medium was added, 0.1 ml at a time, on Day 1 and at Week 1 and Week 2.

Then the cells that had produced the desired antibody were screened by ELISA.

Solutions of GST fusion ribosomal protein L7/L12 and GST protein of *Haemophilus influenzae* dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, each 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C.

After removal of the supernatant, 200 µl of 1 % bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature. After removal of the supernatant, the product was washed with washing solution (0.02 % Tween 20, PBS). One-hundred microliters culture solution of fused cells were added to this and reacted for 2 hours at room temperature. The supernatant was removed and washed with washing solution. Next, 100 µl peroxidase-labeled goat anti-mouse IgG antibody solution at a concentration of 50 ng/ml were added and the solution was reacted for 1 hour at room

temperature. The supernatant was removed and the product was again washed with washing solution. Then TMB solution (KPL Co., ltd) was added, 100  $\mu$ l at a time, and the mixture was reacted for 20 minutes at room temperature. After coloration, 100  $\mu$ l 1 N sulfuric acid were added to stop the reaction and absorbance at 450 nm was determined.

As a result, positive wells that only reacted with GST fusion ribosomal protein L7/L12 and did not react with GST protein were detected, and it was concluded that antibody to ribosomal protein L7/L12 is present.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been cultivated was diluted with HT medium to a cell count of approximately 20 cells/ml and then mixed with  $10^6$  six-week-old mouse thyroid cells suspended in HT Cultivation medium in a 96-well culture plate. Culture was performed for 2 weeks at 37 °C under conditions of 7 % CO<sub>2</sub>.

Antibody activity in the culture supernatant was similarly determined by the aforementioned ELISA method and the cells that showed positive reaction with ribosomal protein L7/L12 were recovered.

Furthermore, the same dilution test and cloning procedure was repeated to obtain a total of 5 clones

of hybridoma HIRB-1 ~ 5.

#### Example 4

Reaction of monoclonal antibody that reacts with  
ribosomal protein L7/L12 of *Haemophilus influenzae*,  
5 with *Neisseria gonorrhoeae* and other microorganisms

Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells obtained as previously described.

Basically,  $5 \times 10^6$  cells that had been  
10 subcultured using RPMI 1640 culture medium  
(containing 10 % FCS) were intraperitoneally injected  
into Balb/C mice that had been intraperitoneally  
injected with 0.5 ml Pristane 2 weeks earlier.  
Ascites was recovered 3 weeks later and the  
15 centrifugation supernatant was obtained.

The solution containing antibody that was  
obtained was adsorbed in a Protein A column (5 ml  
bed, Pharmacia) and washed with 3-bed volume of PBS.  
Then eluted with citrate buffer at pH 3, the antibody  
20 fraction was recovered and the monoclonal antibody  
produced by each hybridoma was obtained.

The monoclonal antibody derived from these 5  
strains of hybridoma was used in ELISA.

The sandwich assay method was used to assess the  
25 monoclonal antibody. The monoclonal antibody that  
was prepared was used as an enzyme-labeled antibody  
by being chemically bound to peroxidase.

That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for  
5 binding using horseradish peroxidase (Sigma Grade VI). By means of the ELISA reaction, a solution of commercial anti-*Haemophilus influenzae* polyclonal antibody which dissolved in PBS containing 0.05 % sodium azide, (Biodesign, rabbit) was diluted to a  
10 concentration of 10 µg/ml and poured, 100 µl at a time, into a separate 96-well plate and adsorbed overnight at 4 °C.

After removal of the supernatant, 200 µl 1 % FCS solution (in PBS) were added and reacted and blocked  
15 for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution (0.02 % Tween 20, PBS). One-hundred microliters of antigen solution, which had been obtained by adding Triton X-100 to culture solutions  
20 of each species of microorganism to a concentration of 0.3 % and then extracting the solution for 5 minutes at room temperature, were added to this and reacted for 2 hours at room temperature. The supernatant was removed and the product was further  
25 washed with washing solution. Then 100 µl peroxidase-labeled anti-ribosomal protein L7/L12 antibody solution at 5 µg/ml were added and reacted

for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution. TMB (KPL Co.) solution was added, 100  $\mu$ l at a time, and reacted for 20 minutes at room

5 temperature. After coloration, 100  $\mu$ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 1 it is clear that when monoclonal antibody derived from hybridoma HIRB-  
10 2 was used as the enzyme-labeled antibody, all strains of *Haemophilus influenzae* tested were detected at a sensitivity of  $10^6$  bacteria/ml, while reactivity of other bacteria belonging to the genus *Neisseria* and other microorganisms could not be  
15 detected, even at high concentrations of  $10^8$  bacteria/ml and therefore, antibody with specific reactivity to *Haemophilus influenzae* can be obtained by using monoclonal antibody to ribosomal protein L7/L12.

20

25

Table 1

Results of Detection (10 <sup>6</sup> cells/ml)		
<i>Haemophilus influenzae</i>	ATCC9327	+
<i>Haemophilus influenzae</i>	ATCC9334	+
<i>Haemophilus influenzae</i>	ATCC9007	+
<i>Haemophilus influenzae</i>	ATCC9332	+
<i>Haemophilus influenzae</i>	ATCC8142	+
<i>Haemophilus influenzae</i>	ATCC9833	+
Results of Detection (10 <sup>8</sup> cells/ml)		
<i>Neisseria meningitides</i>	ATCC13090	—
<i>Neisseria lactamica</i>	ATCC30011	—
<i>Neisseria mucosa</i>	ATCC35611	—
<i>Neisseria sicca</i>	ATCC9913	—
<i>Branhamella catarrharis</i>	ATCC25240	—
<i>Neisseria gonorrhoeae</i>	ATCC9793	—
<i>Escherichia coli</i>	ATCC25922	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—

5 (+: Positive; -: Negative)

#### Example 5

10 Cloning of ribosomal protein L7/L12 genes from  
*Streptococcus pneumoniae*, mass expression in  
*Escherichia coli* and purification of the same protein  
and preparation of monoclonal antibody to the same  
protein

After inoculating an appropriate amount of  
*Streptococcus pneumoniae* strain IID555 (obtained from

Tokyo University School of Medicine Laboratories) in a blood agar culture medium, the strain was cultivated for 48 hours in an incubator at 37 °C. The colonies that grew were suspended in a TE buffer to a  
5 final concentration of approximately  $5 \times 10^9$  CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifuge tube and centrifuged for 2 minutes at 10,000 rpm. The supernatant was discarded. The sediment was resuspended in 567 µl TE  
10 buffer. Then 30 µl 10 % SDS and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated for another hour at 37 °C. Next, after adding 80 µl 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and  
15 thoroughly mixing the product, it was incubated for 10 minutes at 65 °C. Next, 700 µl chloroform-isoamyl alcohol solution at a volume ratio of 24:1 was added and stirred well. The solution was centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm  
20 using a microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was  
25 scooped with a glass rod and transferred to a different microcentrifuge tube containing 1 ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes. Once the supernatant had been removed, the sediment was dissolved in 100  $\mu$ l TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

11/13/89  
13  
PCR was performed using 10 ng of this genomic DNA. Taq polymerase (Takara Co., ltd., code R001A) was employed for PCR. Then 5  $\mu$ l of buffer attached to enzyme, 4  $\mu$ l dNTP mixture attached to enzyme, and 200 pmol each of synthetic oligonucleotide C shown in Sequence No. 13 of the Sequence Table and synthetic oligonucleotide D shown in Sequence No. 14 of the Sequence table were added to the enzyme to bring the final volume to 50  $\mu$ l.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed



in 1.5 % agarose gel using some of this PCR product.  
This product was then stained with ethidium bromide  
(Nihon Gene Co., ltd.) and observed under ultraviolet  
rays to confirm amplification of approximately 400 bp  
5 cDNA. After digestion treatment with restriction  
endonucleases BamHI and XhoI, electrophoresis was  
performed in 1.5 % agarose gel and staining with  
ethidium bromide was carried out. An approximately  
370 bp band was cut out from the gel. This band was  
10 purified with Suprec01 (Takara Co., Ltd.) and then  
inserted into pGEX-6P-1 (Pharmacia), which is a  
commercial vector.

This same vector can function as an expression  
vector for the desired molecule, which can express  
15 fused protein with GST protein, by insertion of the  
desired gene fragment into the appropriate  
restriction endonuclease site. Actually, vector  
pGEX-6P-1 and the previous DNA were mixed together at  
a molar ratio of 1:5 and DNA was inserted into the  
20 vector with T4 DNA ligase (Invitrogen Co.). Vector  
pGEX-4T-1 into which DNA had been inserted was  
genetically introduced to *Escherichia coli* One-Shot  
Competent Cells (Invitrogen Co., Ltd.) and then  
inoculated in a plate of L-Broth (Takara Co., Ltd.)  
25 semi-solid culture plate containing 50 µg/ml  
ampicillin (Sigma). The plate was then set aside at  
37°C for 12 hours and the colonies that grew were

selected at random and inoculated into 2 ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37°C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep (Promega Co.,) in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

Determination of the base sequence of the inserted DNA fragment was performed using the Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5 µl reaction stock solution, 4.0 µl T7 promoter primer at 0.8 pmol/µl (Gibco BRL) and 6.5 µl of template DNA for sequencing at 0.16 µg/µl were added to a microtube with a capacity of 0.5 ml, mixed and superposed with 100 µl mineral oil. PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the reaction was completed, 80 µl sterilized pure water

was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300  $\mu$ l ethanol were added to 100  
5  $\mu$ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing  
10 sample. The sequencing sample was dissolved in formamide containing 4  $\mu$ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing.

One of the 7 clones obtained had homology of the  
15 sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Neisseria gonorrhoeae*, were discovered. The entire base sequence and the  
20 corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 19 and No. 20 of the Sequence Table. This gene fragment clearly codes for *Streptococcus pneumoniae* ribosomal protein L7/L12.

25 50 ml *Escherichia coli* into which expression vector had been inserted was cultivated overnight in a two-fold concentration YT medium at 37 °C. Then,

450 ml of the two-fold concentration YT medium was heated at 37 °C for 1 hour. 50 ml of the *Escherichia coli* solution that had been cultivated overnight was introduced to 450 ml of the aforementioned medium.

- 5 After cultivation for one hour at 37 °C, 100 µl 500 mM IPTG was introduced and cultivated for 4 hours at 25 °C. The product was then recovered and introduced to centrifugation tube at each 250 ml and centrifuged for 20 minutes at 5000 rpm. The supernatant was  
10 discarded and dissolved in 25 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

- Furthermore, 1.25 ml 10 % NP-40 and 125 µl 1 M MgCl<sub>2</sub> were added and transferred to a plastic tube.  
15 Sonication was performed 1 minute x 5 times while ice cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

- Next, the aforementioned supernatant was adsorbed on a glutathione sepharose column (manufactured by  
20 Pharmacia) conditioned with PBS. Then, the column was washed with PBS three times the bed volume. Elution was performed with 50 mM Tris-HCl at a pH of 8.0 containing 10 mM glutathione. The protein content in the fraction was determined by the pigment  
25 bonding method (Bradford method; BioRad Co.) and the main fraction was acquired. The main fraction was dialyzed three times against 3 L PBS.

1 ml of a cleavage buffer containing 500 mM Tris-HCl (pH 7.0), 1.5 M NaCl, 10 mM EDTA, and 10 mM DTT was added to 10 ml of 1 mg/ml solution of the resulting GST fusion ribosomal protein L7/L12. 100  $\mu$ l of 2 u/ $\mu$ l PreScission Protease (manufactured by Pharmacia company) was further added and reacted at 4 °C to separate the GST moiety from ribosomal protein L7/L12.

The reaction solution was passed through a glutathione sepharose column which had been conditioned with PBS. The solution coming out from the column was recovered. One-bed volume of PBS was passed through and also recovered. Purity of the purified ribosomal protein L7/L12 that was obtained was confirmed by electrophoresis to be approximately 90 %, showing that a purity satisfactory for an immunogen could be guaranteed.

First, 100  $\mu$ g protein antigen of ribosomal protein L7/L12 of *Streptococcus pneumoniae* was dissolved in 200  $\mu$ l PBS and then 200  $\mu$ l Freund's complete adjuvant was added and mixed and emulsification was performed. 200  $\mu$ l was intraperitoneally injected to immunize mice. Then, the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4 weeks, and after 6 weeks. A two-fold concentration antigen emulsion was further injected intraperitoneally after 10 weeks and

after 14 weeks. The spleen was excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing  $2 \times 10^7$  myeloma cells per  $10^8$  spleen cells from mice, which had been recovered  
5 aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were  
10 obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5  $\mu$ g/ml MC-210, and 10 % FCS for 1  
15 weeks, and then further cultivating the cell strain for 1 week with an RPMI 1640 medium containing 10 % FCS. 30 ml of RPMI 1640 culture medium 50 ml that had been kept at 37 °C was added to the mixed cell sample and centrifuged at 1,500 rpm. After removal of the  
20 supernatant, 1 ml 50 % polyethylene glycol that had been kept at 37 °C was added and stirred for 2 minute. 10 ml RPMI 1640 medium kept at 37 °C was added and the solution was vigorously mixed for approximately 5 minutes as it was suctioned and  
25 evacuated using a sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm and removal of the supernatant, 30 ml HAT medium were

added to bring the cell concentration to  $5 \times 10^6$  cells/ml. This mixture was stirred till uniform and then poured, 0,1ml at a time, into a 96-well culture plate and cultivated at 37 °C under 7 % CO<sub>2</sub>. HAT  
5 medium was added, 0.1 ml at a time, on Day 1 and at Week 1 and Week 2.

Then, the cells that had produced the desired antibody were screened by ELISA. Solutions of ribosomal protein L7/L12 of *Streptococcus pneumoniae*  
10 dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1 % bovine serum albumin solution (in PBS) were added and  
15 reacted and blocked for 1 hour at room temperature. The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100 µl of a culture solution of fusion cells was added and reacted for two hours at room  
20 temperature. The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl of a peroxidase-labeled goat anti-mouse antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant  
25 was removed and the product was washed with a washing solution. TMB (KPL) solution was added, 100 µl at a time, and reacted for 20 minutes at room temperature.

After coloration, 100  $\mu$ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, positive wells that reacted with  
5 ribosomal protein L7/L12 were detected, confirming presence of the antibody to ribosomal protein L7/L12.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been  
10 cultivated was diluted with an HT medium to a cell count of approximately 20 cells/ml and then mixed with  $10^6$  six-week-old mouse thyroid cells suspended in the HT medium in a 96-well culture plate. The cells were cultivated for 2 weeks at 37 °C under the  
15 conditions of 7 % CO<sub>2</sub>. The antibody activity in the culture supernatant was determined by the aforementioned ELISA method and the cells that showed a positive reaction with ribosomal protein L7/L12 were recovered.

20 Furthermore, the same dilution and cloning procedure was repeated to obtain a total of 4 clones of hybridoma AMSP-1 to 4.

#### Example 6

Reaction of monoclonal antibody that reacts with  
25 ribosomal protein L7/L12 of *Streptococcus pneumoniae*,  
with *Streptococcus pneumoniae* and other  
microorganisms



A monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells obtained as previously described.

5 Specifically, cells subcultured in RPMI 1640 medium (containing 10 % FCS) was diluted with a serum-free medium to about  $2 \times 10^5$  cells/ml,  $3.3 \times 10^5$  cells/ml, and  $5 \times 10^5$  cells/ml in 25 cm<sup>2</sup> culture flasks, and the total volume was made 5 ml. After  
10 cells were grown for 3 to 5 days in 7 % CO<sub>2</sub> at 37 °C, a flask which contains the least number of original cells was selected among flasks in which cells were grown. The same procedure was repeated until the cells diluted to  $2 \times 10^5$  cells/ml grow to  $2 \times 10^6$   
15 cells/ml in 3 to 4 days, thereby adapting the cells with the serum-free medium. Next, cloning was performed in a 96-well plate for bacteria cultivation to select cells exhibiting fastest growth and a highest antibody titer. The selected cells were  
20 grown in a 24-well plate and diluted with a serum-free medium in a 25 cm<sup>2</sup> culture flask to a concentration of about  $2 \times 10^5$  cells/ml and the total volume was made 10 ml. After incubation for 3 to 4 days in 7 % CO<sub>2</sub> at 37 °C to a concentration of  $1 \times 10^6$   
25 cells/ml, the culture broth 100 ml,  $1 \times 10^6$  cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm<sup>2</sup>

flask. 100 ml of a serum-free medium was added to the mixture, which was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquot, the serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain a culture supernatant that contain the target antibody. After the addition of sodium azide to final concentration 0.1 %, the culture supernatant was stored at 4 °C. 100 ml of the solution containing the antibody that was obtained was 5-fold diluted with PBS and adsorbed in a Protein G column (5 ml bed, Pharmacia) and washed with 3-bed volume of PBS. Then eluted with citrate buffer at a pH 3, the antibody fraction was recovered, and monoclonal antibody produced by each hybridoma was obtained. The monoclonal antibodies originating from the four hybridoma clones were evaluated according to the OIA method described in Publication of International Patent Application Japanese Laid-open (Toku-Hyou) No. 509565/1995.

Specifically, the OIA method comprises preparing a reactive substrate by reacting an antibody for

capture on a silicon wafer having a thin film layer of silicon nitride, causing this substrate to react with an antigen which is an extract of microorganisms for a prescribed period of time, causing the captured antigen to react with an antibody (an amplification reagent) which is an enzyme-labeled antibody, and finally adding a substrate solution to produce a thin-film precipitate. The antigen-antibody reaction can be judged visually by a degree of light interference color produced in the precipitate.

The monoclonal antibody preparation was used and evaluated as a capture antibody to be immobilized on a silicon wafer having a silicon nitride thin film layer in the OIA method. Moreover, peroxidase-labeled AMGC-1 monoclonal antibody which can non-specifically react with ribosomal proteins L7/L12 protein of a variety of microorganisms described in Reference Example was used as the detect antibody. That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for binding using horseradish peroxidase (Sigma Grade VI).

In the OIA reaction, monoclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer which has a thin film

layer of silicon nitride, 50  $\mu$ l at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use.

15  $\mu$ l of antigen solution, which had been  
5 obtained by adding 0.5% Triton X-100 to culture solutions of various species of microorganisms and then extracting the solution for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10  
10 minutes at room temperature. Then, 15  $\mu$ l of 20  $\mu$ g/ml peroxidase-labeled AMGC1 anti-body was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL) was added, 15  $\mu$ l at a time, and reacted for 5 minutes at room  
15 temperature. The product was washed with distilled water to judge the concentration of detection signals as an intensity of light interference by naked eyes.

As a result, as shown in Table 2 it is clear that when monoclonal antibody derived from hybridoma AMSP-  
20 2 was used as the capture antibody, all strains of *Streptococcus pneumoniae* tested were detected at a sensitivity of  $10^6$  bacteria/ml, while reactivity of other bacteria could not be detected at a higher concentration of  $10^8$  bacteria/ml. Thus, the antibody  
25 with specific reactivity to *Streptococcus pneumoniae* was confirmed to have been obtained by using the monoclonal antibody to ribosomal protein L7/L12.

The hybridoma AMSP-2 which produces the monoclonal antibody specific to *Streptococcus pneumoniae* has been deposited with National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan, on July 28, 1999, with the disposition number FERM BP-6807.

Table 2

Results of Detection (10 <sup>6</sup> cells/ml)		
<i>Streptococcus pneumoniae</i>	ATCC27336	+
<i>Streptococcus pneumoniae</i>	IID554	+
<i>Streptococcus pneumoniae</i>	IID555	+
<i>Streptococcus pneumoniae</i>	IID556	+
<i>Streptococcus pneumoniae</i>	IID557	+
<i>Streptococcus pneumoniae</i>	IID558	+
<i>Streptococcus pneumoniae</i>	IID559	+
<i>Streptococcus pneumoniae</i>	IID1603	+
Results of Detection (10 <sup>8</sup> cells/ml)		
<i>Escherichia coli</i>	ATCC25922	-
<i>Enterococcus faecalis</i>	ATCC19433	-
<i>Haemophilus influenzae</i>	ATCC10211	-
<i>Klebsiella pneumoniae</i>	ATCC13883	-
<i>Neisseria gonorrhoeae</i>	IID821	-
<i>Neisseria lactamica</i>	ATCC23970	-
<i>Neisseria meningitides</i>	ATCC13090	-
<i>Pseudomonas aeruginosa</i>	ATCC27853	-
Group B streptococcus	ATCC12386	-
<i>Staphylococcus aureus</i>	ATCC25923	-
<i>Streptococcus pyogenes</i>	ATCC19615	-

(+: Positive; -: Negative)

Example 7

Cloning of ribosomal protein L7/L12 genes from  
*Neisseria gonorrhoeae*, mass expression in *Escherichia*  
*coli* and purification of the same protein and  
5 preparation of monoclonal antibody to the same  
protein

1WS  
B14  
1 After inoculating an appropriate amount of  
*Neisseria gonorrhoeae* strain IID821 (obtained from  
Tokyo University School of Medicine Laboratories) in  
10 a chocolate agar culture medium, the strain was  
cultivated for 24 hours in a CO<sub>2</sub> incubator under  
conditions of 37 °C and 0.5 <5.0> % CO<sub>2</sub>. The colonies  
that grew were suspended in a TE buffer to a final  
concentration of approximately 5 x 10<sup>9</sup> CFU/ml.  
15 Approximately 1.5 ml of this suspension was  
transferred to a microcentrifugation tube and  
centrifuged for 2 minutes at 10,000 rpm. The  
supernatant was discarded. The sediment was  
resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS  
20 and 3 µl 20 mg/ml Proteinase K solution were added  
and thoroughly mixed. The suspension was incubated  
for another hour at 37 °C.

Next, after adding 80 µl 10 % cetyl trimethyl  
ammonium bromide/0.7 M NaCl solution and thoroughly  
25 mixing the product, it was incubated for 10 minutes  
at 65 °C. Next, 700 µl chloroform-isoamyl alcohol  
solution at a volume ratio of 24:1 was added and

stirred well. The solution was centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm using a microcentrifugation device and the aqueous fraction was transferred to a new microtube.

- 5 Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifugation tube containing 1 ml 70  
10 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes.

- 15 Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination  
20 of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

- INS  
BIS  
25 1 PCR was performed using 10 ng of this genomic DNA. PCR was performed using Taq polymerase (Takara Co., Ltd., code R001A). Then, 5 µl of a buffer attached to enzyme, 4 µl of a dNTP mixture attached

to enzyme, and 200 pmol each of synthetic oligonucleotide E shown in Sequence No. 15 of the Sequence Table and synthetic oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were  
5 designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet Information (Oklahoma University, N. *Gonorrhoeae* Genome Project, disclosed genomic DNA data) because of the similarity with ribosomal  
10 protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50  $\mu$ l.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes  
15 at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide  
20 (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with  
25 ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then



inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA ligase (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* One-Shot Competent Cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing 50 µg/ml ampicillin (Sigma). The plate was then set aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37°C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

INS  
B16  
Determination of the base sequence of the inserted DNA fragment was performed using the Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied

Biosystems). First, 9.5  $\mu$ l reaction stock solution, 4.0  $\mu$ l T7 promoter primer at 0.8 pmol/ $\mu$ l (Gibco BRL) and 6.5  $\mu$ l template DNA for sequencing at 0.16  $\mu$ g/ $\mu$ l were added to a microtube with a capacity of 0.5 ml and mixed. After layering with 100  $\mu$ l mineral oil, PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the reaction was completed, 80  $\mu$ l sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300  $\mu$ l ethanol were added to 100  $\mu$ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4  $\mu$ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing. One of the 5 clones obtained had homology of the sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example,

*Haemophilus influenzae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence No. 21 and No. 22 of the Sequence Table.

5 This gene fragment clearly codes for ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*.

*Neisseria gonorrhoeae* fusion GST ribosome protein L7/L12 prepared by the same method as in Example 2 was obtained using the *Neisseria gonorrhoeae* fusion  
10 GST ribosomal protein L7/L12 expression vector constructed in this way.

Furthermore, hybridoma strain GCRB-3, which produces monoclonal antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, was obtained in  
15 accordance with the method in Example 3.

#### Example 8

Reaction of monoclonal antibody that reacts with ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, with *Neisseria gonorrhoeae* and other microorganisms

20 Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells GCRB-3 obtained as previously described.

Basically,  $5 \times 10^6$  cells (in PBS) that had been  
25 subcultured using RPMI 1640 culture medium (containing 10 % FCS) were intraperitoneally injected into Balb/C mice that had been intraperitoneally

injected with 0.5 ml Pristane 2 weeks earlier.  
Ascites was recovered 3 weeks later and the  
centrifugation supernatant was obtained.

The solution containing antibody that was  
5 obtained was adsorbed in a Protein A column (5 ml  
bed, Pharmacia) and washed with 3-bed volume of PBS.  
Then eluted with citrate buffer at pH 3, the antibody  
fraction was recovered and the monoclonal antibody  
that was produced by each hybridoma was obtained.  
10 The monoclonal antibody derived from the GCRB-3  
hybridoma was used in ELISA.

The sandwich assay method was used to assess the  
monoclonal antibody. The monoclonal antibody that  
was prepared was used as an enzyme-labeled antibody  
15 by being chemically bound to peroxidase. That is,  
enzyme labeling was performed in accordance with the  
method in "Analytical Biochemistry" 132 (1983), 68-73  
with the reagent S-acetylthioacetic acid N-  
hydroxysuccinimide for binding using horseradish  
20 peroxidase (Sigma Grade VI). By means of the ELISA  
reaction, a solution of commercial anti-*Neisseria*  
*gonorrhoeae* polyclonal antibody in PBS containing  
0.05% sodium azide (Virostat, rabbit) was diluted to a  
concentration of 10 µg/ml and poured, 100 µl at a  
25 time, into a separate 96-well plate and adsorbed  
overnight at 4 °C.

After removal of the supernatant, 200 µl 1 %

bovine serum albumin solution (in PBS) were added and reacted for 1 hour and blocked at room temperature. The supernatant was removed and the product was washed with washing solution (0.02 % Tween 20, PBS).

- 5 One-hundred microliters of antigen solution, which had been obtained by adding Triton X-100 to culture solutions of each species of microorganisms to a concentration of 0.3 % and then extracting the solution for 5 minutes at room temperature, were
- 10 added to this and reacted for 2 hours at room temperature. The supernatant was removed and the product was further washed with washing solution. Then 100  $\mu$ l peroxidase-labeled anti-ribosomal protein L7/L12 antibody solution at 5  $\mu$ g/ml were added and
- 15 reacted for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution. TMB (KPL) solution was added, 100  $\mu$ l at a time, and reacted for 20 minutes at room temperature. After coloration, 100  $\mu$ l 1 N sulfuric
- 20 acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 3 it is clear that when monoclonal antibody derived from hybridoma GCRB-3 was used as the enzyme-labeled antibody, all

25 strains of *Neisseria gonorrhoeae* tested were detected at a sensitivity of  $10^6$  cells/ml, while reactivity of other species belonging to the genus *Neisseria* and

other microorganisms could not be detected, even at high concentrations of  $10^8$  cells/ml and therefore, antibody with specific reactivity to *Neisseria gonorrhoeae* can be obtained by using monoclonal antibody to ribosomal protein L7/L12.

Table 3

Results of Detection ( $10^6$ cells/ml)		
<i>Neisseria gonorrhoeae</i>	ATCC9793	+
<i>Neisseria gonorrhoeae</i>	ATCC19424	+
<i>Neisseria gonorrhoeae</i>	ATCC27628	+
<i>Neisseria gonorrhoeae</i>	ATCC27629	+
<i>Neisseria gonorrhoeae</i>	ATCC27630	+
<i>Neisseria gonorrhoeae</i>	ATCC27631	+
<i>Neisseria gonorrhoeae</i>	ATCC27632	+
<i>Neisseria gonorrhoeae</i>	ATCC27633	+
<i>Neisseria gonorrhoeae</i>	ATCC35541	+
<i>Neisseria gonorrhoeae</i>	ATCC35542	+
<i>Neisseria gonorrhoeae</i>	ATCC43069	+
<i>Neisseria gonorrhoeae</i>	ATCC43070	+
<i>Neisseria gonorrhoeae</i>	ATCC49226	+
Results of Detection ( $10^8$ cells/ml)		
<i>Neisseria meningitidis</i>	ATCC13090	—
<i>Neisseria lactamica</i>	ATCC30011	—
<i>Neisseria mucosa</i>	ATCC35611	—
<i>Neisseria sicca</i>	ATCC9913	—
<i>Branhamella catarrharis</i>	ATCC25240	—
<i>Haemophilus influenzae</i>	ATCC10211	—
<i>Escherichia coli</i>	ATCC25922	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—

10 (+: Positive; -: Negative).

Example 9

Acquisition of ant-ribosomal protein L7/L12  
monoclonal antibody specific to genus *Neisseria*

5 After inoculating an appropriate amount of  
*Neisseria gonorrhoeae* strain IID821 (obtained from  
Tokyo University School of Medicine Laboratories) in  
a chocolate agar culture medium, the strain was  
cultivated for 24 hours in a CO<sub>2</sub> incubator under  
10 conditions of 37 °C and 0.5 <5.0> % CO<sub>2</sub>. The colonies  
that grew were suspended in a TE buffer to a final  
concentration of approximately 5 x 10<sup>9</sup> CFU/ml.  
Approximately 1.5 ml of this suspension was  
transferred to a microcentrifugation tube and  
15 centrifuged for 2 minutes at 10,000 rpm. The  
supernatant was discarded. The sediment was  
resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS  
and 3 µl 20 mg/ml Proteinase K solution were added  
and thoroughly mixed. The suspension was incubated  
20 for another hour at 37 °C. Next, after adding 80 µl  
10 % cetyl trimethyl ammonium bromide/0.7 M NaCl  
solution and thoroughly mixing the product, it was  
incubated for 10 minutes at 65 °C. Next, 700 µl  
chloroform-isoamyl alcohol solution at a volume ratio  
25 of 24:1 was added and stirred well.

The solution was centrifuged for 5 minutes (while  
being kept at 4 °C) at 12,000 rpm using a

microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifugation tube containing 1 ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes. Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

PCR was performed using 10 ng of this genomic DNA. Taq polymerase (Takara Co., Ltd., code R001A) was employed for PCR. Then, 5 µl buffer attached to enzyme, 4 µl dNTP mixture attached to enzyme, and 200 pmol each of synthetic oligonucleotide E shown in Sequence No. 15 of the Sequence Table and synthetic



oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet information

5 (Oklahoma University, *N. Gonorrhoeae* Genome Project, disclosed genome DNA data) because of the similarity with ribosomal protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50  $\mu$ l.

10 This mixture was cycled 5 times with a TaKaRa PCR Thermal Cyclor 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed  
15 in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction  
20 endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then  
25 inserted into pGEX-6P-1 (Pharmacia), which is a commercial vector. This same vector can function as an expression vector for the desired molecule, which

can express fused protein with GST protein, by  
insertion of the desired gene fragment into the  
appropriate restriction endonuclease site. Actually,  
vector pGEX-6P-1 and the previous DNA were mixed  
5 together at a molar ratio of 1:5 and DNA was inserted  
into the vector with T4 DNA ligase (Invitrogen Co.).  
Vector pGEX-6P-1 into which DNA had been inserted was  
genetically introduced to *Escherichia coli* One-Shot  
Competent Cells (Invitrogen Co., Ltd.) and then  
10 inoculated in a plate of L-Broth (Takara Co., ltd.)  
semi-solid culture plate containing 50 µg/ml  
ampicillin (Sigma). The plate was then set aside at  
37 °C for 12 hours and the colonies that grew were  
selected at random and inoculated into 2 ml L-Broth  
15 liquid culture medium containing the same  
concentration of ampicillin. Shake cultivation was  
performed at 37 °C for 8 hours and the bacteria was  
recovered and the plasmid was separated using Wizard  
Miniprep in accordance with the attached literature.  
20 The plasmid was cleaved with restriction endonuclease  
BamHI/XhoI. Insertion of said PCR product was  
confirmed by cutting out approximately 370 bp DNA.  
The base sequence of the DNA that had been inserted  
was determined using said clone.

25 Determination of the base sequence of the  
inserted DNA fragment was performed using the  
Fluorescence Sequencer of Applied Biosystems. The

sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5  $\mu$ l reaction stock solution, 4.0  $\mu$ l T7 promoter primer at 0.8 pmol/ $\mu$ l (Gibco BRL) and 6.5  $\mu$ l template DNA for sequencing at 0.16  $\mu$ g/ $\mu$ l were added to a microtube with a capacity of 0.5 ml and mixed. After layering with 100  $\mu$ l mineral oil, PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the reaction was completed, 80  $\mu$ l sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300  $\mu$ l ethanol were added to 100  $\mu$ l the aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4  $\mu$ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing.

One of the 4 clones obtained had homology of the sequence with the probe used for PCR. In addition,

DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Haemophilus influenzae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 21 and No. 22 of the Sequence Table. This gene fragment clearly codes for *Neisseria gonorrhoeae* ribosomal protein L7/L12.

50 ml *Escherichia coli* into which expression vector had been inserted was cultivated overnight in a two-fold concentration YT medium at 37 °C. Then, 450ml of the two-fold concentration YT medium was heated at 37 °C for 1 hour. 50 ml of the *Escherichia coli* solution that had been cultivated overnight was introduced to 450ml of the aforementioned medium. After cultivation for one hour at 37 °C, 100 µl 500 mM IPTG was introduced and cultivated for 4 hours at 25 °C. The product was then recovered and introduced 250 ml each to a centrifugation tube and centrifuged for 20 minutes at 5000 rpm. The supernatant was discarded and dissolved in 25 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

Furthermore, 1.25 ml 10% NP-40 and 125 µl 1 M MgCl<sub>2</sub> were added and transferred to a plastic tube. Sonication was performed 1 minute x 5 times while ice

cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

Next, the aforementioned supernatant was adsorbed on a glutathione sepharose column (manufactured by Pharmacia) conditioned with PBS. Then, the column was washed with PBS three times the bed volume. Elution was performed with 50 mM Tris-HCl at a pH of 8.0 containing 10 mM glutathione. The protein content in the fraction was determined by the pigment bonding method (Bradford method; BioRad Co.) and the main fraction was acquired. The main fraction was dialyzed three times against 3L PBS.

1 ml of a cleavage buffer containing 500 mM Tris-HCl (pH 7.0), 1.5 M NaCl, 10 mM EDTA, and 10 mM DTT was added to 10 ml of 1 mg/ml solution of the resulting GST fusion ribosomal protein L7/L12. 100  $\mu$ l of 2 u/ $\mu$ l PreScission Protease (manufactured by Pharmacia company) was further added and reacted at 4 °C to separate the GST moiety from ribosomal protein L7/L12.

The reaction solution was passed through a glutathione sepharose column which had been conditioned with PBS. The solution coming out from the column was recovered. One bed volume of PBS was passed through and also recovered. Purity of the purified ribosomal protein L7/L12 that was obtained was confirmed by electrophoresis to be approximately

90 %, showing that a purity satisfactory for an immunogen could be guaranteed.

First, 100 µg protein antigen of ribosomal protein L7/L12 of *Neisseria gonorrhoeae* was dissolved in 200 µl PBS and then 200 µl Freund's complete adjuvant was added and mixed and emulsification was performed. 200 µl was intraperitoneally injected to immunize mice. Then, the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4 weeks, and after 6 weeks. A two-fold concentration antigen emulsion was further injected intraperitoneally after 10 weeks and after 14 weeks. The spleen was excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing  $2 \times 10^7$  myeloma cells per  $10^8$  spleen cells from mice, which had been recovered aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5 µg/ml MC-210, and 10 % FCS for 1 weeks, and then further cultivating the cell strain

for 1 week with an RPMI 1640 medium containing 10 % FCS. 30 ml of RPMI 1640 culture medium 50 ml that had been kept at 37°C was added to the mixed cell sample and centrifuged at 1,500 rpm. After removal of the supernatant, 1 ml 50 % polyethylene glycol that had been kept at 37 °C was added and stirred for 2 minute. 10 ml RPMI 1640 medium kept at 37 °C was added and the solution was vigorously mixed for approximately 5 minutes as it was suctioned and evacuated from a sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm and removal of the supernatant, 30 ml HAT culture medium were added to bring the cell concentration to  $5 \times 10^6$  cells/ml. This mixture was stirred till uniform and then poured, 0.1 ml at a time, into a 96-well culture plate and cultivated at 37 °C under 7 % CO<sub>2</sub>. HAT medium was added, 0.1 ml at a time, on Day 1 and at Week 1 and Week 2.

Then the cells that had produced the desired antibody were assessed by ELISA. Solutions of ribosomal protein L7/L12 of *Neisseria gonorrhoeae* dissolved in PBS containing 0.05 % sodium azide were diluted to 10 µg/ml and were poured, 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1 % bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature.

The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100  $\mu$ l of a culture solution of fusion cells was added and reacted for two hours at room temperature.

5 The supernatant was removed and the product was further washed with a washing solution. Then, 100  $\mu$ l of a peroxidase-labeled goat anti-mouse antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant was removed and the product was washed with a washing solution. TMB (KPL) solution was added, 100  $\mu$ l at a time, and reacted for 20 minutes at room temperature. After coloration, 100  $\mu$ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was  
10 determined.  
15

As a result, positive wells that reacted with ribosomal protein L7/L12 were detected, confirming presence of the antibody to ribosomal protein L7/L12.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been  
20 cultivated was diluted with an HT medium to a cell count of approximately 20 cells/ml. Then 50  $\mu$ l the medium was mixed with  $10^6$  six-week-old mouse thyroid  
25 cells suspended in the HT medium in a 96-well culture plate. The cells were cultivated for 2 weeks at 37 °C under the conditions of 7 % CO<sub>2</sub>. The antibody titer in



the culture supernatant was determined by the  
aforementioned ELISA method and, the cells those  
showed a positive reaction with ribosomal protein  
L7/L12 were recovered. Furthermore, the same dilution  
5 and cloning procedure was repeated to obtain a total  
of 4 clones of hybridoma AMGC-5 to AMGC-8.

Monoclonal antibody was produced and recovered  
according to standard methods, using the positive  
hybridoma cells obtained as previously described.

10 Specifically, cells subcultured in RPMI 1640  
medium (containing 10 % FCS) was diluted in serum-  
free medium to about  $2 \times 10^5$  cells/ml,  $3.3 \times 10^5$   
cells/ml, and  $5 \times 10^5$  cells/ml in 25 cm<sup>2</sup> culture flask,  
and the total was made 5 ml. After cells were grown  
15 for 3 to 5 days in 7 % CO<sub>2</sub> at 37 °C, flask that  
contains the least number of original cells was  
selected among flasks in which cells were grown. The  
same procedure was repeated until the cells diluted  
to  $2 \times 10^5$  cells/ml grow to  $2 \times 10^6$  cells/ml in 3 to 4  
20 days, thereby adapting the cells with serum-free  
medium. Next, cloning was performed in a 96-well  
plate for bacterial culture to select cells  
exhibiting fastest growth and a highest antibody  
titer. The selected cells were grown in a 24-well  
25 plate and diluted with a serum-free medium in a 25  
cm<sup>2</sup> culture flask to a concentration of about  $2 \times 10^5$   
cells/ml and the total volume was made to 10 ml.

After incubation for 3 to 4 days in 7 % CO<sub>2</sub> at 37 °C to a concentration of 1 x 10<sup>6</sup> cells/ml, the culture broth 100 ml, 1 x 10<sup>6</sup> cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm<sup>2</sup> flask. 100 ml of a serum-free medium was added to the mixture and was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquots, one volume serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain culture supernatant containing the target antibody. After adding sodium azide to final concentration 0.1 %, the culture supernatant was stored at 4 °C. 100 ml of the supernatant containing the antibody was diluted 5-fold with PBS and adsorbed in a protein G column (5 ml bed, Pharmacia) and washed with 3-bed volume of PBS. Then eluted with citrate buffer at pH 3, the antibody fraction was recovered and monoclonal antibody produced by each hybridoma was obtained.

The monoclonal antibodies originating from the four hybridoma clones were evaluated according to the

OIA method described in International Patent  
Application Japanese Laid-open No. 509565/1995.

Specifically, the OIA method comprises preparing  
a reactive substrate by reacting an antibody for  
capture on a silicon wafer having a thin film layer  
of silicon nitride, causing this substrate to react  
with an antigen which is an extract of microorganisms  
for a prescribed period of time, causing the captured  
antigen to react with an antibody (an amplification  
reagent) which is an enzyme-labeled antibody, and  
finally adding a substrate solution to produce a  
thin-film precipitate. The antigen-antibody reaction  
can be judged visually by a degree of light  
interference color produced in the precipitate.

The monoclonal antibody preparation was used as a  
capture antibody to be immobilized on a silicon wafer  
having a silicon nitride thin film layer in the OIA  
method. Moreover, peroxidase-labeled AMGC-1  
monoclonal antibody which can non-specifically react  
with ribosomal proteins L7/L12 protein of a variety  
of microorganisms described in Reference Example was  
used as the detect antibody. That is, enzyme  
labeling was performed in accordance with the method  
in "Analytical Biochemistry" 132 (1983), 68-73 with  
the reagent S-acetylthioacetic acid N-  
hydroxysuccinimide for binding using horseradish  
peroxidase (Sigma Grade VI).

In the OIA reaction, monoclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer which has a thin film layer of silicon nitride, 50 µl at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use. 15 µl of antigen solution, which had been obtained by adding 0.5 % Triton X-100 to culture suspension of various species of microorganisms and then extracting the suspension for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10 minutes at room temperature. Then, 15 µl of 20 µg/ml peroxidase-labeled AMGC1 was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL Co.) was added, 15 µl at a time, and reacted for 5 minutes at room temperature. The product was washed with distilled water to judge the concentration of detection signals as an intensity of light interference by naked eyes.

As a result, as shown in Table 4 it is clear that when monoclonal antibody derived from hybridoma AMGC-8 was used as the capture antibody, all strains of *Neisseria* genus tested were detected at a sensitivity of  $10^8$  cells/ml, while reactivity of other microorganisms could not be detected. Thus, the

antibody with specific reactivity to *Neisseria* genus was confirmed to have been obtained by using the monoclonal antibody to ribosomal protein L7/L12.

5 Table 4

Results of Detection (10 <sup>8</sup> cells/ml)		
<i>Neisseria gonorrhoeae</i>	IID821	+
<i>Neisseria lactamica</i>	ATCC23970	+
<i>Neisseria meningitidis</i>	ATCC13090	+
<i>Escherichia coli</i>	ATCC25922	—
<i>Enterococcus faecalis</i>	ATCC19433	—
<i>Haemophilus influenzae</i>	ATCC10211	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—
<i>Pseudomonas aeruginosa</i>	ATCC27853	—
Group B streptococcus	ATCC12386	—
<i>Staphylococcus aureus</i>	ATCC25923	—
<i>Streptococcus pneumoniae</i>	ATCC27336	—
<i>Streptococcus pyogenes</i>	ATCC19615	—

(+: Positive; -: Negative)

10 Example 10

Acquisition of a polyclonal antibody which specifically reacts with ribosomal protein L7/L12 of *Haemophilus influenzae* using a ribosomal protein L7/L12 protein-immobilized affinity column

15 A centrifugal supernatant of *Haemophilus influenzae* cell extract, which had been treated with 0.5% Triton X-100 was used as an antigen. About 1.2 ml of a physiological saline solution containing 100

µg of antigen was emulsified with the addition of 1.5 ml of Freund's adjuvant. The emulsion was subcutaneously injected into four SPF Japanese White Rabbits to immunize the animals. The rabbits were immunized 5 to 6 times, once every two weeks, and the antibody titer was confirmed.

The antibody titer was confirmed by the ELISA method. Solutions of ribosomal protein L7/L12 of *Haemophilus influenzae* dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, 100 µl at a time, into 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1 % bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature. The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100 µl of a solution obtained by diluting normal rabbit serum and immunized rabbit antiserum was added and reacted for two hours at room temperature. The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl of a peroxidase-labeled goat anti-rabbit IgG antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant was removed and the product was washed with a washing solution. OPD solution (Sigma Co.) was added, 100 µl at a time, and reacted for 20

minutes at room temperature. After coloration, 100  $\mu$ l of 1 N sulfuric acid was added to stop the reaction. Absorbance at 492 nm was determined.

After confirming that the antibody titer had increased, a large quantity of blood was collected. Blood was collected in a centrifugal tube made of glass from the ear artery, allowed to stand for one hour at 37 °C, then overnight at 4 °C. The mixture was centrifuged at 3000 rpm for 5 minutes and the supernatant was recovered. The resulting 4 lots of anti-serum were stored at 4 °C.

Next, an affinity column with immobilized ribosomal protein L7/L12 of *Haemophilus influenzae* and *Neisseria gonorrhoeae* was prepared. HiTrap NHS-activated column (1 ml, manufactured by Pharmacia) was used. Immediately after replacing the column with 6 ml of 1 mM HCl, 1 ml of a PBS solution of ribosomal protein L7/L12 adjusted to 1 mg/ml was charged. The column was allowed to stand for 15 minutes at 25 °C. This procedure was repeated 5 times, thereby feeding the total 5 ml of the PBS solution of ribosomal protein L7/L12. Then, 6 ml of Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3), 6 ml of Buffer B (0.1 M acetic acid, 0.5 M NaCl, pH 4), and 6 ml of Buffer A were charged as blocking reagents. After allowing to stand for 15 minutes at 25 °C, 6 ml of Buffer B, 6 ml of Buffer A, and 6 ml

of Buffer B were further added. The mixture was then equilibrated with 6 ml of PBS.

Using the affinity column with immobilized ribosomal protein L7/L12 of *Haemophilus influenzae*,  
5 the polyclonal antibody in the resulting anti-serum was purified using the supernatant of Triton X-100 treated bacteria of *Haemophilus influenzae* as an antigen. This antiserum was first diluted with PBS to a volume of 5 times, passed through a 0.45  $\mu$ m filter,  
10 then caused to be adsorbed in the column immobilized with ribosomal protein L7/L12 of *Haemophilus influenzae* at a flow rate of 0.5 ml/min. After elution from the column with 0.1 M glycine (pH 2.1) and immediately neutralizing with 1 M Tris-HCl (pH  
15 9.0), eluted fractions of the target antibody were recovered by the ELISA method, the same as anti-titer measuring method. These fractions were passed through the affinity column immobilized with the ribosomal protein L7/L12 of *Neisseria gonorrhoeae*,  
20 which was equilibrated with PBS whereby the antibody that reacts with the ribosomal protein L7/L12 of *Neisseria gonorrhoeae* was adsorbed and fraction which passed through without adsorption was recovered.

The polyclonal antibody purified in this manner  
25 was evaluated by the same OIA method as in Example 6.

The purified antibody was used as a capture antibody for the OIA method. Moreover, peroxidase-



labeled AMGC-1 monoclonal antibody described in Reference Example was used as the detect antibody. That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for binding using horseradish peroxidase (Sigma Grade VI).

In the OIA reaction, the purified polyclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer, 50 µl at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use.

15 µl of antigen solution, which had been obtained by adding 0.5 % Triton X-100 to culture suspension of various species of microorganisms and then extracting the suspension for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10 minutes at room temperature. Then, 15 µl of 20 µg/ml peroxidase-labeled AMGC1 was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL) was added, 15 µl at a time, and reacted for 5 minutes at room temperature. The product was washed with distilled water to observe the blue color concentration by the naked eyes.

As a result, as shown in Table 5 it is clear that

when the purified polyclonal antibody of APhi2-2 was used as the capture antibody, *Haemophilus influenzae* tested at a sensitivity of  $10^8$  bacteria/ml was detected, while reactivity of other microorganisms could not be detected. Thus, the antibody with specific reactivity to *Haemophilus influenzae* was confirmed to have been obtained by using the polyclonal antibody purified by an affinity column immobilized with the ribosomal protein L7/L12 of *Haemophilus influenzae*.

Table 5

		Results of Detection ( $10^8$ cells/ml)
<i>Haemophilus influenzae</i>	ATCC10211	+
<i>Escherichia coli</i>	ATCC25922	—
<i>Enterococcus faecalis</i>	ATCC19433	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—
<i>Neisseria gonorrhoeae</i>	IID821	—
<i>Neisseria lactamica</i>	ATCC23970	—
<i>Neisseria meningitidis</i>	ATCC13090	—
<i>Pseudomonas aeruginosa</i>	ATCC27853	—
Group B <i>Streptococcus</i>	ATCC12386	—
<i>Staphylococcus aureus</i>	ATCC25923	—
<i>Streptococcus pneumoniae</i>	ATCC27336	—
<i>Streptococcus pyogenes</i>	ATCC19615	—

(+: Positive; -: Negative)

Reference Example 1

Acquisition of monoclonal antibody that reacts non-specifically with ribosomal protein L7/L12 of various bacteria

So called sandwich assay in which an antigen is  
5 sandwiched between a capture antibody and a labeled  
antibody for detection is useful to detect  
microorganisms by optical immunoassay and the ELISA  
method because of its high detection sensitivity. In  
this instance, not only an antibody which  
10 specifically reacts with antigens originating from  
the subject microorganism, but also another antibody  
which recognizes an antigen epitope different from  
that of the specific antibody are required.

Antibodies which react non-specifically with  
15 ribosomal protein L7/L12 originating various  
microorganisms are very useful as an antibody which  
can constitute a sandwich assay with an antibody  
which reacts specifically with ribosomal protein  
L7/L12.

20 Fortunately, ribosomal proteins L7/L12 protein of  
a variety of microorganisms have a region wherein the  
amino acid sequence is homologous. Here, the  
inventors have been successful in acquiring a  
monoclonal antibody which exhibits a cross reaction  
25 with ribosomal proteins L7/L12 protein of various  
species of microorganisms from *Neisseria gonorrhoeae*.  
It has been discovered that an antibody to anti-

ribosomal protein L7/L12 having no specificity, which was acquired from one species of microorganisms can be used for sandwich assay of several kinds of microorganisms.

5        Cloning of ribosomal protein L7/L12 genes from *Neisseria gonorrhoeae*, mass expression in *Escherichia coli* and purification of the same protein, and preparation of monoclonal antibody to the same protein were performed.

10        After inoculating an appropriate amount of *Neisseria gonorrhoeae* strain IID821 (obtained from Tokyo University School of Medicine Laboratories) in a chocolate agar culture medium, the strain was cultivated for 24 hours in a CO<sub>2</sub> incubator under  
15        conditions of 37 °C and 0.5 <5.0> % CO<sub>2</sub>. The colonies that grew were suspended in a TE buffer to a final concentration of approximately 5 x 10<sup>9</sup> CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifugation tube and  
20        centrifuged for 2 minutes at 10,000 rpm. The supernatant was discarded. The sediment was resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated  
25        for another hour at 37 °C. Next, after adding 80 µl 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and thoroughly mixing the product, it was

incubated for 10 minutes at 65 °C. Next, 700 µl  
chloroform-isoamyl alcohol solution at a volume ratio  
of 24:1 was added and stirred well. The solution was  
centrifuged for 5 minutes (while being kept at 4 °C)  
5 at 12,000 rpm using a microcentrifugation device and  
the aqueous fraction was transferred to a new  
microtube. Isopropanol was added to the fraction at  
0.6-times its volume and the tube was vigorously  
shaken to form sediment of the DNA. The white DNA  
10 sediment was scooped with a glass rod and transferred  
to a different microcentrifugation tube containing 1  
ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes  
at 10,000 rpm and the supernatant was gently removed.  
15 Then another 1 ml 70 % ethanol was added and the  
product was centrifuged for 5 more minutes. Once the  
supernatant had been removed, the sediment was  
dissolved in 100 µl TE buffer to obtain the DNA  
solution. The concentration of the genomic DNA  
20 solution was determined quantitatively in accordance  
with E5, Spectrophotometric determination of the  
amount of DNA or RNA, "Molecular cloning: A  
laboratory manual," 1989, Eds. Sambrook, J., Fritsch,  
E.F., and Maniatis, T., Cold Spring Harbor Laboratory  
Press.

25  
B29  
1 PCR was performed using 10 ng of this genomic  
DNA. Taq polymerase (Takara Co., Ltd., code R001A)

was employed for PCR. Then, 5  $\mu$ l of a buffer attached to enzyme, 4  $\mu$ l of dNTP mixture attached to enzyme, and 200 pmol of each of synthetic oligonucleotide E shown in Sequence No. 15 of the Sequence Table and synthetic oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet information (Oklahoma University, N. Gonorrhoeae Genome Project, disclosed genomic DNA data) because of the similarity with ribosomal protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50  $\mu$ l.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately

370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA ligase (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* One-Shot Competent Cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing 50 µg/ml ampicillin (Sigma). The plate was then set aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2 ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37 °C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

135  
B20  
1 Determination of the base sequence of the inserted DNA fragment was performed using the

Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5  $\mu$ l reaction stock solution, 4.0  $\mu$ l T7 promoter primer at 0.8 pmol/ $\mu$ l (Gibco BRL) and 6.5  $\mu$ l template DNA for sequencing at 0.16  $\mu$ g/ $\mu$ l were added to a microtube with a capacity of 0.5 ml and mixed. After superposition with 100  $\mu$ l mineral oil, PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 5 minutes at 60 °C. The product was then kept at 4 °C for 4 minutes. After the reaction was completed, 80  $\mu$ l sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300  $\mu$ l ethanol were added to 100  $\mu$ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4  $\mu$ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing. One of the 5 clones obtained had homology of the sequence with the probe



used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Haemophilus influenzae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence No. 21 and No. 22 of the Sequence Table. This gene fragment clearly codes for *Neisseria gonorrhoeae* ribosomal protein L7/L12.

*Neisseria gonorrhoeae* GST fused ribosome protein L7/L12 prepared by the same method as in Example 2 was obtained using the *Neisseria gonorrhoeae* GST fusion ribosomal protein L7/L12 expression vector constructed in this way. Furthermore, hybridoma strain AMGCl, which produces monoclonal antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, was obtained in accordance with the method similar to the method of Example 3. Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells of AMGCl strain obtained as previously described.

Specifically, cells subcultured in RPMI 1640 medium (containing 10 % FCS) was diluted with a serum-free medium to about  $2 \times 10^5$  cells/ml,  $3.3 \times 10^5$  cells/ml, and  $5 \times 10^5$  cells/ml in 25 cm<sup>2</sup> culture flasks, and the total was made 5 ml. After cell were grown for 3 to 5 days in 7 % CO<sub>2</sub> at 37 °C, a flask

which contains the least number of original cells was selected among flasks in which cells were grown. The same procedure was repeated until the cells diluted to  $2 \times 10^5$  cells/ml grow to  $2 \times 10^6$  cells/ml in 3 to 4 days, thereby adapting the cells with the serum-free medium. Next, cloning was performed in a 96-well plate for bacteria cultivation to select cells exhibiting fastest growth and a highest antibody titer. The selected cells were grown in a 24-well plate and diluted with a serum-free medium in a 25 cm<sup>2</sup> culture flask to a concentration of about  $2 \times 10^5$  cells/ml and the total volume was made 10 ml. After incubation for 3 to 4 days in 7 % CO<sub>2</sub> at 37 °C to a concentration of  $1 \times 10^6$  cells/ml, the culture broth 100 ml,  $1 \times 10^6$  cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm<sup>2</sup> flask. 100 ml of a serum-free medium was added to the mixture, which was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquots, the serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain a

culture supernatant including the target antibody. After the addition of sodium azide to final concentration 0.1 %, the culture supernatant was stored at 4 °C. 100 ml of the solution containing the antibody that was obtained was diluted 5-fold with PBS and adsorbed in a Protein A column (5 ml bed volume, Pharmacia) and washed with 3-bed volume of PBS. Then eluted with citrate buffer at pH 3, the antibody fraction was recovered and monoclonal antibody produced by each hybridoma was obtained. The monoclonal antibody derived from the hybridoma was used in ELISA.

To evaluate the antibody, 96-well plates sensitized with ribosomal proteins L7/L12 of various microorganisms were used as an antigen. The monoclonal antibody prepared was reacted, followed by the reaction of horseradish peroxidase-labeled anti-mouse IgG (manufactured by MBL, Code 330) as a secondary antigen, and finally the antibody was detected using an enzyme reaction coloring reagent. In the ELISA reaction, solutions of recombinant ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* dissolved in PBS containing 0.05 % sodium azide diluted to 1 µg/ml were poured, 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1%

bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature.

The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20,

5 PBS). Solutions of AMGC1 antibody, at concentrations of 0.1-1 µg/ml, in an amount of 100 µl each, were added and reacted for two hours at room temperature. The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl  
10 of a solution of 5 µg/ml horse radish peroxidase-labeled anti-mouse IgG (manufactured by MBL, Code 330) was added and reacted for one hour at room temperature. The supernatant was removed and the product was washed with a washing solution. TMB (KPL)  
15 solution was added, 100 µl at a time, and reacted for 20 minutes at room temperature. After coloration, 100 µl 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 6 it was confirmed  
20 that when the monoclonal antibody originating from hybridoma AMGC1 was used, this antibody can react with ribosomal proteins L7/L12 of all bacteria such as *Neisseria gonorrhoeae*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*.

25 Table 6

Results of detection of AMGC1 antibody and Ribosomal Protein L7/L12 of microorganisms
---

<i>Neisseria gonorrhoeae</i>	+
<i>Haemophilus influenzae</i>	+
<i>Streptococcus pneumoniae</i>	+

(+: Positive)

The AMGC1 antibody obtained here is very useful  
 5 as an antibody used for the detection of  
 microorganisms in the so-called sandwich assay by  
 optical immunoassay and ELISA method, in combination  
 with an anti-ribosomal protein L7/L12 antibody which  
 is specific to each microorganism.

#### 10 Industrial Applicability

According to the present invention, not only  
 microorganisms can be detected specifically according  
 to species, but also microorganisms of all serotypes  
 15 in the same species can be detected at a high  
 precision, by using antibodies to intracellular  
 molecules of the same function.

By using antibodies to ribosomal proteins L7/L12  
 of various microorganisms as such antibodies,  
 20 *Haemophilus influenzae* and *Neisseria gonorrhoeae* can  
 be detected precisely.

Moreover, specific antibodies used for the  
 detection of various kinds of microorganisms can be  
 prepared by using intracellular molecules exhibiting  
 25 same functions in various microorganisms as an

antigen.

REMARKS TO DEPOSITED MICROORGANISMS

The organization in which the microorganisms have been deposited:

- 5           National Institute of Bioscience and Human  
            Technology, the Agency of Industrial Science  
            and Technology

Address: 1-1-3, Higashi, Yatabe-cho, Tsukuba-shi,  
          Ibaraki-ken, Japan (Postal Code: 305).

- 10   Date of deposition: July 28, 1999

Number of deposition given by the deposition  
organization: FERM BP-6807

INS  
B22